• Johnson & Johnson presented atrial fibrillation ablation study results for VARIPULSE Pro and investigational OMNYPULSE at APHRS 2026 in Busan, South Korea.
• VARIPURE found successful procedures across all patients treated with VARIPULSE Pro; one serious safety event resolved without lasting effects.
• OMNYPULSE showed sustained rhythm control at 12 months, improved quality of life and reduced cardiovascular-related hospitalizations; all reported safety events resolved.
• VARIPULSE Pro is available in Europe, Japan and other Asia-Pacific and Latin American markets but lacks US approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022589385) on October 22, 2026, and is solely responsible for the information contained therein.